Safety and efficacy of REP 2139 and pegylated interferon...

  • Main
  • 2017 / 9
  • Safety and efficacy of REP 2139 and pegylated interferon...

Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial

Bazinet, Michel, Pântea, Victor, Cebotarescu, Valentin, Cojuhari, Lilia, Jimbei, Pavlina, Albrecht, Jeffrey, Schmid, Peter, Le Gal, Frédéric, Gordien, Emmanuel, Krawczyk, Adalbert, Mijočević, Hrvoje,
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Language:
english
Journal:
The Lancet Gastroenterology & Hepatology
DOI:
10.1016/S2468-1253(17)30288-1
Date:
September, 2017
File:
PDF, 838 KB
english, 2017
Conversion to is in progress
Conversion to is failed